CoChat
Sign Up
Cited by 21

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

Tian, Ling, Chen, Congcong, Guo, Yanguan, Zhang, Fan, Mi, Jinye, Feng, Qi, Lin, Shengbin, Xi, Naite, Tian, Jiaxin, Yu, Li, Chen, Yan, Cao, Mingrong, Lai, Caiyong, Fan, Jun, Zhang, Yongchang, Chen, Guo·2021·Neoplasia
DOI 10.1016/j.neo.2021.05.007PMC PMC8215139
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neo.2021.05.007

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inhibition of mTORC2 signaling extends the lifespan of C. elegans under certain temperatures and dietary conditions, has anti-tumor effects, is beneficial in mouse models of mitochondrial disease, and has been shown to inhibit or reverse senescence in human cells.

    “Inhibition of mTORC2 signaling extends the lifespan of C. elegans under certain temperatures and dietary conditions111,112, has anti-tumor effects 128–131, is beneficial in mouse models of mitochondrial disease132,133, and has been shown to inhibit or reverse senescence in human cells 134,135.”

    From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [130]

    Only the anti-tumor clause is attributed to this source; the other clauses have separate citations. The Results section, “Targeting mTORC2 sensitize NSCLC to gemcitabine in vivo” (page unavailable), reports anti-tumor effects when mTORC1/2 inhibition was combined with gemcitabine in NSCLC xenografts. It does not establish the unqualified claim that mTORC2 inhibition has anti-tumor effects on its own. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 31

  1. Halbrook, 2019, Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer, Cell Metab, 29, 1390, 10.1016/j.cmet.2019.02.001 · DOI · Paper page
  2. O'Shaughnessy, 2014, Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer, J Clin Oncol, 32, 3840, 10.1200/JCO.2014.55.2984 · DOI · Paper page
  3. Zhang, 2013, Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC, Mol Ther, 21, 1559, 10.1038/mt.2013.120 · DOI
  4. Boeckemeier, 2020, Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication, Sci Adv, 6, eaaz4126, 10.1126/sciadv.aaz4126 · DOI
  5. Wang, 2007, Enhanced subunit interactions with gemcitabine-5′-diphosphate inhibit ribonucleotide reductases, Proc Natl Acad Sci U S A, 104, 14324, 10.1073/pnas.0706803104 · DOI · Paper page
  6. Raoof, 2014, Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks, J Natl Cancer Inst, 106, 10.1093/jnci/dju183 · DOI
  7. Koh, 2016, Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells, BMC Genomics, 17, 1029, 10.1186/s12864-016-3322-x · DOI
  8. Liao, 2012, Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum, J Thorac Oncol, 7, 973, 10.1097/JTO.0b013e31824fe98c · DOI
  9. Mlak, 2016, The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient, Clin Transl Oncol, 18, 915, 10.1007/s12094-015-1461-1 · DOI
  10. Primo, 2019, DNA replication stress: oncogenes in the spotlight, Genet Mol Biol, 43
  11. Smith, 2014, A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response, Nucleic Acids Res, 42, 11517, 10.1093/nar/gku840 · DOI
  12. Saxton, 2017, mTOR signaling in growth, metabolism, and disease, Cell, 168, 960, 10.1016/j.cell.2017.02.004 · DOI · Paper page
  13. Guri, 2017, mTORC2 promotes tumorigenesis via lipid synthesis, Cancer Cell, 32, 807, 10.1016/j.ccell.2017.11.011 · DOI
  14. Cheng, 2015, RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors, Cancer Discov, 5, 1262, 10.1158/2159-8290.CD-14-0971 · DOI
  15. Tanaka, 2011, Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance, Cancer Discov, 1, 524, 10.1158/2159-8290.CD-11-0124 · DOI
  16. Xu, 2017, MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling, Sci Rep, 7, 41718, 10.1038/srep41718 · DOI
  17. Gu, 2017, mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT, Mol Cell, 67, 128, 10.1016/j.molcel.2017.05.030 · DOI
  18. Zhang, 2010, mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis, Cancer Res, 70, 9360, 10.1158/0008-5472.CAN-10-0207 · DOI
  19. Zhang, 2019, mTORC2-mediated PDHE1alpha nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma, Oncogene, 38, 4669, 10.1038/s41388-019-0749-y · DOI
  20. Shimada, 2013, TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks, Mol Cell, 51, 829, 10.1016/j.molcel.2013.08.019 · DOI
  21. Chen, 2019, Acetylation regulates ribonucleotide reductase activity and cancer cell growth, Nat Commun, 10, 3213, 10.1038/s41467-019-11214-9 · DOI · Paper page
  22. Poli, 2012, dNTP pools determine fork progression and origin usage under replication stress, EMBO J, 31, 883, 10.1038/emboj.2011.470 · DOI
  23. Feldman, 2009, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol, 7, e38, 10.1371/journal.pbio.1000038 · DOI
  24. Kim, 2018, Replication stress shapes a protective chromatin environment across fragile genomic regions, Mol Cell, 69, 36, 10.1016/j.molcel.2017.11.021 · DOI
  25. Turinetto, 2015, Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions, Nucleic Acids Res, 43, 2489, 10.1093/nar/gkv061 · DOI
  26. Cerqueira, 2007, Understanding ribonucleotide reductase inactivation by gemcitabine, Chemistry, 13, 8507, 10.1002/chem.200700260 · DOI
  27. Boukovinas, 2008, Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients, PLoS One, 3, e3695, 10.1371/journal.pone.0003695 · DOI
  28. Ben-Sahra, 2017, mTORC1 signaling and the metabolic control of cell growth, Curr Opin Cell Biol, 45, 72, 10.1016/j.ceb.2017.02.012 · DOI
  29. Rozman Grinberg, 2018, Novel ATP-cone-driven allosteric regulation of ribonucleotide reductase via the radical-generating subunit, Elife, 7, 10.7554/eLife.31529 · DOI
  30. Driscoll, 2016, mTORC2 signaling drives the development and progression of pancreatic cancer, Cancer Res, 76, 6911, 10.1158/0008-5472.CAN-16-0810 · DOI
  31. Gkountakos, 2018, Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex, Carcinogenesis, 39, 971, 10.1093/carcin/bgy086 · DOI

Cited by

Sorted by citations

Metadata

Authors
Tian, L., Chen, C., Guo, Y., Zhang, F., Mi, J., Feng, Q., Lin, S., Xi, N., Tian, J., Yu, L., Chen, Y., Cao, M., Lai, C., Fan, J., Zhang, Y., & Chen, G.
ORCID
Venue
Neoplasia
Publisher
Elsevier BV
Published
2021-07
Volume
23
Issue
7
Pages
643-652
ISSN
1476-5586
DOI
10.1016/j.neo.2021.05.007
PMC
PMC8215139
Cited by
21
References
4
Language
en
Licence
Funders
  • National Natural Science Foundation of China (82073042)
  • Natural Science Foundation of Guangdong Province (2019A1515011247)
  • Guangzhou Municipal Science and Technology Project (202002030451)
  • Fundamental Research Funds for the Central Universities (21620421)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review